Physician

Muhammad Rafiuddin, MD

According to 2025 Medicare claims, Muhammad Rafiuddin, MD (NPI: 1487879599) practices nephrology in the Cincinnati, OH-KY-IN market, with the plurality of this provider's patient population coming from Boone, KY. This provider's primary affiliated billing organization is KIDNEY ASSOCIATES OF THE TRISTATE (NPI: 1831730183; TIN: 84-3046513) and primary practice location at 41017-3403. Rafiuddin is affiliated with the Healthcare Solutions Network (ACO ID: A3283), participating under the MSSP model.

Rafiuddin's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 338 traditional Medicare patients, billed 1,854 HCPCS/CPT codes, and received $184,776 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 2,978 prescription claims across 387 beneficiaries totaling $79,537 in drug costs, led by Sevelamer Carbonate (Sevelamer Carbonate). DME data shows 53 claims. Open Payments data shows 1 records totaling $17. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $116,940 and ending at $184,776. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $28,311 and ending at $79,537. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	371	1,324	$116,940
2016	345	1,583	$137,124
2017	401	1,681	$136,432
2018	420	2,048	$191,466
2019	371	1,586	$150,699
2020	376	2,093	$211,284
2021	366	1,932	$197,862
2022	331	1,751	$173,043
2023	323	1,630	$157,661
2024	338	1,854	$184,776

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	114	846	$28,311
2016	178	1,805	$219,613
2017	225	2,265	$358,212
2018	287	2,293	$124,073
2019	303	2,405	$122,129
2020	326	2,623	$186,051
2021	324	2,538	$133,781
2022	311	2,451	$199,617
2023	339	2,697	$207,209
2024	387	2,978	$79,537

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	53	$850

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	23	23	$147
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	116	145	$129
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	156	576	$89
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	169	313	$85
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	100	470	$59

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Sevelamer Carbonate	Sevelamer Carbonate	37	2,270	$7,029
Potassium Citrate Er	Potassium Citrate	62	3,512	$4,037
Midodrine Hcl	Midodrine Hcl	49	2,469	$2,895
Torsemide	Torsemide	192	10,406	$2,568
Nifedipine Er	Nifedipine	106	7,440	$2,497

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	21	$351
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	13	$254
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	19	$245

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$17	Travere Therapeutics, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Muhammad Rafiuddin, MD?

Tedicare shows public-source Medicare data for Muhammad Rafiuddin, MD (NPI 1487879599), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Muhammad Rafiuddin, MD have ACO affiliation data?

Muhammad Rafiuddin, MD is shown with ACO affiliation data for Healthcare Solutions Network (MSSP, ACO ID A3283).

What billing organization is linked to Muhammad Rafiuddin, MD?

Muhammad Rafiuddin, MD is linked to KIDNEY ASSOCIATES OF THE TRISTATE (billing NPI 1831730183) in the available physician profile data.

Does Muhammad Rafiuddin, MD have Open Payments data?

Muhammad Rafiuddin, MD has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.